The hearing will be the panel’s second in two weeks examining the rising cost of insulin in the U.S.
Rep. Diana DeGette, D-Colo, chairman of the committee, told The Hill that the panel also will hear from three of the largest pharmacy benefit managers about their role in driving insulin costs up.
Eli Lilly, Novo Nordisk and Sanofi control 99 percent of the world’s insulin. Lawmakers are asking them to explain their pricing.
Before the hearing, Express Scripts, a PBM that merged with health insurer Cigna in 2018, launched an insurance plan that caps insulin costs for patients at $25 a month.
More articles on pharmacy:
10 hospitals seeking pharmacy leadership
Patent protection clause is latest stumbling block for revised NAFTA
Dr. Reddy’s legal win expected to lower cost of opioid addiction treatment
